Phase 2 data have shown promising efficacy with nivolumab combined with ipilimumab in this patient population, and data already published from the ongoing, phase 3 CheckMate 8HW trial show ...

Dr. Emre Yekedüz discusses his top 3 key takeaways from attending the 2025 ASCO Genitourinary (GU) Cancers Symposium.

The primary endpoint was progression-free survival (PFS; nivolumab/ipilimumab vs chemotherapy and nivolumab/ipilimumab vs nivolumab monotherapy). Findings showed the risk of disease progression or ...

Adding tilsotolimod to ipilimumab did not improve response or survival outcomes in patients with advanced melanoma.

During a live event, Thach-Giao Truong, MD, moderated a discussion on treating a 78-year-old patient with metastatic melanoma ...

Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...

A breakthrough cancer treatment plan could be a "cure" for a death sentence form of the disease. An experimental new ...

The article by Doshi et al entitled “Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the ...

Evaluating the efficacy of cabozantinib in patients with advanced renal cell carcinoma with bone metastasis: An open-label phase 2 study. This is an ASCO Meeting Abstract from the 2025 ASCO ...